Apogee Therapeutics Inc (NASDAQ: APGE) kicked off on Tuesday, down -10.87% from the previous trading day, before settling in for the closing price of $32.30. Over the past 52 weeks, APGE has traded in a range of $29.10-$63.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -51.71%. With a float of $36.94 million, this company’s outstanding shares have now reached $45.99 million.
Let’s determine the extent of company efficiency that accounts for 196 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Apogee Therapeutics Inc (APGE) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Apogee Therapeutics Inc is 37.92%, while institutional ownership is 81.96%. The most recent insider transaction that took place on Apr 02 ’25, was worth 139,801. In this transaction Chief Medical Officer of this company sold 3,860 shares at a rate of $36.22, taking the stock ownership to the 247,173 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Officer proposed sale 9,310 for $35.61, making the entire transaction worth $331,529.
Apogee Therapeutics Inc (APGE) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -51.71% per share during the next fiscal year.
Apogee Therapeutics Inc (NASDAQ: APGE) Trading Performance Indicators
Take a look at Apogee Therapeutics Inc’s (APGE) current performance indicators. Last quarter, stock had a quick ratio of 18.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.23, a number that is poised to hit -1.24 in the next quarter and is forecasted to reach -5.99 in one year’s time.
Technical Analysis of Apogee Therapeutics Inc (APGE)
Looking closely at Apogee Therapeutics Inc (NASDAQ: APGE), its last 5-days average volume was 0.98 million, which is a jump from its year-to-date volume of 0.66 million. As of the previous 9 days, the stock’s Stochastic %D was 18.41%. Additionally, its Average True Range was 3.17.
During the past 100 days, Apogee Therapeutics Inc’s (APGE) raw stochastic average was set at 7.43%, which indicates a significant decrease from 17.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.74% in the past 14 days, which was lower than the 75.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.90, while its 200-day Moving Average is $45.42. However, in the short run, Apogee Therapeutics Inc’s stock first resistance to watch stands at $33.38. Second resistance stands at $37.97. The third major resistance level sits at $41.56. If the price goes on to break the first support level at $25.20, it is likely to go to the next support level at $21.61. Should the price break the second support level, the third support level stands at $17.02.
Apogee Therapeutics Inc (NASDAQ: APGE) Key Stats
The company with the Market Capitalisation of 1.71 billion has total of 45,027K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -182,150 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -67,220 K.
